Pharma Pulse: FDA Ends 40-Year Drought for Motion Sickness

Welcome to Pharma Pulse, a Pharmaceutical Commerce podcast where we bring you the latest insights shaping patient access, supply chain/logistics, data & tech, and healthcare innovation. I’m your host, and let’s get into today’s headlines.

• First, a breakthrough for millions of travelers. The FDA has approved Vanda Pharmaceuticals’ Nereus, also known as tradipitant, for the prevention of vomiting induced by motion sickness. This oral NK-1 receptor antagonist marks the first new pharmacological treatment for the condition in over 40 years. In pivotal trials conducted at sea, Nereus demonstrated a significant reduction in vomiting compared to placebo.
• Hoth Therapeutics is doubling down on its oncology-focused dermatology platform. The company officially filed two US provisional patent applications for its lead candidate, HT-001. These filings target skin toxicities caused by radiation and emerging cancer therapies, such as menin inhibitors, which often cause severe rashes that force patients to halt treatment.

That’s it for this episode of Pharma Pulse. For more insights on trends transforming pharmaceutical access and care delivery, visit pharmaceuticalcommerce.com.

Thanks for listening—until next time, stay well and stay informed.

You can catch Pharma Pulse directly on Audioboom, Spotify, or iHeart.